U.S. imports of Alkaloid-Containing Medicaments (Not in Dosage Form, NESOI) (HS 300349) totaled $2.1M in August 2026, imported from 7 countries.
Importers of Alkaloid-Containing Medicaments (Not in Dosage Form, NESOI) paid $38K in duties in August 2026, an average duty rate of 1.81% — duty actually collected as a share of the imports that cleared customs, not the published tariff schedule. Alkaloid-Containing Medicaments (Not in Dosage Form, NESOI) imports of $2.1M in August 2026 ran 71% above the year-to-date monthly average of $1.2M.
Last updated: August 2026 dataCovering alkaloid-based pharmaceutical preparations not elsewhere specified and not put up in measured doses, tariff line 3003490000 captures a broad range of plant-derived and synthetic alkaloid APIs — from opioid precursors to antimalarial compounds — that fall outside the pseudoephedrine-specific line. India leads US imports under this heading, followed by Taiwan, the United Kingdom, Denmark, and Canada, a supplier mix that reflects both generic API manufacturing capacity and originator pharmaceutical operations. Depending on the specific alkaloid, DEA scheduling requirements may apply in addition to standard FDA import procedures, making pre-import regulatory screening essential. Importers should verify whether the alkaloid in question is a controlled substance or listed chemical before shipment.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
5 import shipments a month
The importer should cross-reference the alkaloid's CAS number against DEA's schedules of controlled substances and list of listed chemicals. If the substance appears on either list, DEA registration and, where applicable, import quota compliance are required before the shipment can enter. FDA registration of the foreign establishment is a separate, parallel requirement.
Customs and FDA will look at the commercial invoice, certificate of analysis, and packaging to confirm the product is a bulk API or intermediate rather than a packaged, measured-dose product. Key indicators include labeling in kilograms rather than unit doses, absence of patient-facing labeling, and a drug master file reference rather than an NDA/ANDA number. Mischaracterizing a finished product as bulk API to avoid dosage-form classification is a compliance risk.
Trade Directory
List your company under HS 300349 — Alkaloid-Containing Medicaments (Not in Dosage Form, NESOI), so the companies trading it can find you. Be the first supplier listed.
Subheading 3 of 10 in heading 3003
Subheading 300349 · $2.1M of $70.5M
ImportsExports
Imports
$2.1MYoY · free account
Exports
$644KYoY · free account
Low of 11 reported months · imports
Low · free accountOver the twelve months to August 2026, the U.S. imported $15.4M of Alkaloid-Containing Medicaments (Not in Dosage Form, NESOI) and exported $11.3M.
Through August 2026 · imports 11 of 12 months reported. Source: U.S. Census Bureau.
Imports · August 2026
origin
India and United Kingdom together supply 100% of it.
customs district
destination
entry
rate provision · imports
81.9% enters free of duty; duty collected equals 1.81% of imports for consumption.
HS10 import codes under this HS6 parent, each with its own page. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Imports for consumption | Average duty rate | Dutiable Share | Duty Collected |
|---|---|---|---|---|---|
| 3003490000 | Other Medicaments Containing Alkaloids/Derivat | $2.1M | 1.81% | 18.13% | $38K |
HS10 export codes under this HS6 parent, each with its own page. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 3003490000 | Other Medicaments Containing Alkaloids/Derivat | $644K |
Import lines come from the U.S. Harmonized Tariff Schedule and export lines from Schedule B. The two are numbered by different agencies, so the same 10-digit code can appear in both tables describing a different product.